Menu
GeneBe

CLCN7

chloride voltage-gated channel 7, the group of Chloride voltage-gated channels|Protein phosphatase 1 regulatory subunits

Basic information

Region (hg38): 16:1444933-1475077

Links

ENSG00000103249NCBI:1186OMIM:602727HGNC:2025Uniprot:P51798AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autosomal dominant osteopetrosis 2 (Supportive), mode of inheritance: AD
  • autosomal recessive osteopetrosis (Supportive), mode of inheritance: AR
  • autosomal recessive osteopetrosis 6 (Supportive), mode of inheritance: AR
  • autosomal recessive osteopetrosis 4 (Strong), mode of inheritance: AR
  • hypopigmentation, organomegaly, and delayed myelination and development (Strong), mode of inheritance: AD
  • autosomal dominant osteopetrosis 2 (Strong), mode of inheritance: AD
  • hypopigmentation, organomegaly, and delayed myelination and development (Moderate), mode of inheritance: AD
  • autosomal dominant osteopetrosis 2 (Definitive), mode of inheritance: AD
  • autosomal recessive osteopetrosis 4 (Definitive), mode of inheritance: AR
  • autosomal recessive osteopetrosis 4 (Definitive), mode of inheritance: AR
  • autosomal dominant osteopetrosis 2 (Strong), mode of inheritance: AD
  • autosomal recessive osteopetrosis 4 (Strong), mode of inheritance: AR
  • hypopigmentation, organomegaly, and delayed myelination and development (Limited), mode of inheritance: AD
  • autosomal dominant osteopetrosis 2 (Limited), mode of inheritance: Semidominant

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Osteopetrosis, autosomal dominant 2; Osteopetrosis, autosomal recessive 4AD/ARAllergy/Immunology/Infectious; Hematologic; MusculoskeletalIn Autosomal recessive osteopetrosis, early diagnosis can allow medical treatment related to calcium homeostasis, including prevention/treatment of hypocalcemic seizures; Transfusions for hematologic manifestations may be necessary; Individuals may benefit from infectious prophylaxis and early and aggressive treatments of infections; HSCT has been described as beneficial; In Autosomal dominant forms of Osteopetrosis, avoidance of high-fracture risk activities can be beneficial, and calcitriol has been reported as beneficialAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Craniofacial; Dermatologic; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Ophthalmologic18131787; 13665485; 4871758; 6546410; 3377922; 2268972; 8358946; 10617161; 11741829; 11207362; 12522560; 13130312; 14584882; 17033731; 17164308; 20301306; 23296056; 31155284

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CLCN7 gene.

  • not provided (868 variants)
  • Osteopetrosis (151 variants)
  • Autosomal recessive osteopetrosis 4 (31 variants)
  • Inborn genetic diseases (30 variants)
  • Autosomal dominant osteopetrosis 2 (26 variants)
  • not specified (21 variants)
  • Hypopigmentation, organomegaly, and delayed myelination and development (16 variants)
  • Increased bone mineral density (12 variants)
  • Autosomal dominant osteopetrosis 2;Autosomal recessive osteopetrosis 4;Hypopigmentation, organomegaly, and delayed myelination and development (2 variants)
  • Autosomal recessive osteopetrosis 4;Autosomal dominant osteopetrosis 2 (2 variants)
  • Hypopigmentation, organomegaly, and delayed myelination and development;Autosomal recessive osteopetrosis 4;Autosomal dominant osteopetrosis 2 (2 variants)
  • CLCN7-related condition (1 variants)
  • Abnormality of the skeletal system (1 variants)
  • See cases (1 variants)
  • Hypopigmentation, organomegaly, and delayed myelination and development;Autosomal dominant osteopetrosis 2;Autosomal recessive osteopetrosis 4 (1 variants)
  • Connective tissue disorder (1 variants)
  • Autosomal dominant osteopetrosis 2;Hypopigmentation, organomegaly, and delayed myelination and development;Autosomal recessive osteopetrosis 4 (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CLCN7 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
6
clinvar
193
clinvar
14
clinvar
213
missense
13
clinvar
19
clinvar
249
clinvar
16
clinvar
1
clinvar
298
nonsense
5
clinvar
1
clinvar
6
start loss
0
frameshift
10
clinvar
3
clinvar
13
inframe indel
6
clinvar
6
splice donor/acceptor (+/-2bp)
1
clinvar
6
clinvar
5
clinvar
12
splice region
35
42
2
79
non coding
2
clinvar
51
clinvar
134
clinvar
108
clinvar
295
Total 31 28 318 343 123

Highest pathogenic variant AF is 0.0000328

Variants in CLCN7

This is a list of pathogenic ClinVar variants found in the CLCN7 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
16-1444946-C-T Osteopetrosis Likely benign (Jan 13, 2018)317902
16-1444964-G-A Osteopetrosis Uncertain significance (Jan 12, 2018)886153
16-1444986-C-G Osteopetrosis Benign (Jan 12, 2018)317903
16-1445005-C-G Osteopetrosis Benign (Jan 13, 2018)317904
16-1445006-AACC-A Osteopetrosis Likely benign (Jun 14, 2016)317905
16-1445008-C-A Osteopetrosis Uncertain significance (Jan 15, 2018)887168
16-1445024-C-A Osteopetrosis Uncertain significance (Jan 13, 2018)887169
16-1445042-C-G Osteopetrosis Likely benign (Jan 13, 2018)317906
16-1445058-C-T Osteopetrosis Uncertain significance (Jan 13, 2018)887170
16-1445059-G-A Osteopetrosis Likely benign (Jan 13, 2018)887171
16-1445133-G-GC Osteopetrosis Uncertain significance (Jun 14, 2016)317907
16-1445140-G-A Osteopetrosis Uncertain significance (Jan 12, 2018)317908
16-1445179-C-T Osteopetrosis Likely benign (Jan 13, 2018)317909
16-1445210-C-G Osteopetrosis Uncertain significance (Jan 13, 2018)317910
16-1445228-T-G Osteopetrosis Uncertain significance (Jan 12, 2018)317911
16-1445242-T-G Osteopetrosis Benign (Jan 13, 2018)317912
16-1445263-C-T Osteopetrosis Uncertain significance (Jan 12, 2018)888425
16-1445299-G-A Osteopetrosis Benign (Jan 13, 2018)317913
16-1445301-G-A Osteopetrosis Uncertain significance (Apr 27, 2017)888426
16-1445334-A-G Osteopetrosis Uncertain significance (Jan 13, 2018)317914
16-1445338-C-T Osteopetrosis Uncertain significance (Jan 13, 2018)317915
16-1445342-C-T Osteopetrosis Uncertain significance (Jan 13, 2018)885322
16-1445383-C-T Osteopetrosis Uncertain significance (Jan 13, 2018)317916
16-1445416-G-T Osteopetrosis Uncertain significance (Jan 13, 2018)885323
16-1445442-C-T Osteopetrosis Uncertain significance (Jan 13, 2018)317917

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CLCN7protein_codingprotein_codingENST00000382745 2530647
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.2720.7281257150231257380.0000915
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense2.113584900.7310.00003495100
Missense in Polyphen92179.970.511211769
Synonymous-3.062832251.260.00001851649
Loss of Function4.661043.00.2320.00000224473

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001780.000177
Ashkenazi Jewish0.0002000.000198
East Asian0.000.00
Finnish0.00004620.0000462
European (Non-Finnish)0.00009850.0000967
Middle Eastern0.000.00
South Asian0.00009800.0000980
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Slowly voltage-gated channel mediating the exchange of chloride ions against protons. Functions as antiporter and contributes to the acidification of the lysosome lumen. {ECO:0000269|PubMed:18449189, ECO:0000269|PubMed:21527911}.;
Disease
DISEASE: Osteopetrosis, autosomal dominant 2 (OPTA2) [MIM:166600]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA2 is the most common form of osteopetrosis, occurring in adolescence or adulthood. It is characterized by sclerosis, predominantly involving the spine, the pelvis and the skull base. {ECO:0000269|PubMed:11741829, ECO:0000269|PubMed:14584882, ECO:0000269|PubMed:19288050, ECO:0000269|PubMed:19953639, ECO:0000269|PubMed:26395888}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Osteopetrosis, autosomal recessive 2 (OPTB2) [MIM:259710]: A rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. Osteopetrosis occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Recessive osteopetrosis commonly manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. {ECO:0000269|PubMed:26395888}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Stimuli-sensing channels;Ion channel transport;Transport of small molecules (Consensus)

Recessive Scores

pRec
0.298

Intolerance Scores

loftool
0.0468
rvis_EVS
-1.64
rvis_percentile_EVS
2.82

Haploinsufficiency Scores

pHI
0.238
hipred
Y
hipred_score
0.685
ghis
0.625

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.835

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Clcn7
Phenotype
pigmentation phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; respiratory system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); renal/urinary system phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype;

Gene ontology

Biological process
response to pH;chloride transmembrane transport
Cellular component
nucleoplasm;lysosomal membrane;membrane;integral component of membrane;cytoplasmic vesicle
Molecular function
voltage-gated chloride channel activity;chloride channel activity;protein binding;ATP binding;antiporter activity